SANOFI US SERVICES INC.

Lobbying for SANOFI US SERVICES INC

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$2,540,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 15

HR 7174
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 946
ORPHAN Cures Act
HR 1503
Prescription Information Modernization Act of 2023
HR 2880
Protecting Patients Against PBM Abuses Act
HR 5376
Impacts and Outcomes for Health Career Training Act
HR 830
HELP Copays Act
HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025
S 1339
Pharmacy Benefit Manager Reform Act
S 864
HELP Copays Act
S 1542
DRUG Act
S 2916
Prescription Information Modernization Act of 2023
S 4504
SCREEN for Type 1 Diabetes Act of 2024
HR 8698
SCREEN for Type 1 Diabetes Act of 2024

Lobbying activity 6

Manufacturing

Drug Pricing - General Issues; Taxes- General Issues; Tax Credits; Insurance Design.

Health Issues

340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S. 832; EPIC Act; CDC Type 1 Diabetes Awareness and Education: LHHS approps; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness: LHHS approps; COPD Research Funding: LHHS approps; Delinking; Drug Price Negotiations; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; HR 946- Orphan Drug Negotiation: Orphan Cures Act; HR 1503: Prescription Information Modernization Act of 2023; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376: Inflation Reduction Act; HR 830: HELP Copays Act; HRSA - Type 1 Diabetes Screening: LHHS approps; Influenza Vaccines; Insulin Pricing-General; Insurance Design; Intellectual Property; Out of Pocket Cap (OOP); Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 1262/ S. 932: Give Kids a Chance Act; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 1339: PBM Reform Act; S. 864: HELP Copays Act; S. 1542: DRUG Act; S. 2916: Prescription Information Modernization Act of 2023; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Type 1 Diabetes Screening; Vaccine Injury Compensation Program; Vaccines-General Issues.

Medicare/Medicaid

340B; Medicaid Drug Rebate Program Rule; Medicare Negotiation.

Trade (domestic/foreign)

Insulin; Supply Chain Issues.

Taxation/Internal Revenue Code

Pharmacy Benefits Managers (PBMs); Supply Chain; Taxes-General Issues; TCJA Expiration - Tax Cuts and Jobs Act; Transplant; Vaccine Injury Compensation Program.

Intellectual Property.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.